Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

EU authorises Aimmune’s peanut allergy treatment Palforzia

Approval in the EU comes nine months after US authorisation

- PMLiVE

Pfizer/BioNTech COVID-19 vaccine set for roll-out in Germany this month

Germany will begin vaccinating elderly in care homes on 27 December

- PMLiVE

EU fast-tracks review of Pfizer/BioNTech COVID-19 vaccine

CHMP meeting scheduled for 21 December

- PMLiVE

AstraZeneca to acquire Alexion for $39bn

Deal will bolster AZ's portfolio with rare disease assets

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

- PMLiVE

AZ divests European rights for cholesterol med Crestor to Grünenthal

Grünenthal will pay up to $350m for the rights

- PMLiVE

AZ, Oxford University face more scrutiny over COVID-19 vaccine data

WHO’s immunisations director says ‘more than a press release’ is needed

EU flag

EU buys 160 million doses of Moderna’s COVID-19 vaccine

Deal follows positive data readout last week

- PMLiVE

AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%

Across two dosing regimens, vaccine has average efficacy of 70%

- PMLiVE

Chief investigator of Oxford Vaccine Group says data could be released before Christmas

AstraZeneca is developing a COVID-19 vaccine with Oxford University

- PMLiVE

AZ’s COVID-19 vaccine proves promising in elderly participants, new data shows

Immune responses were similar in younger and older adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links